Cargando…
The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells
Disease recurrence is the major problem in the treatment of acute myeloid leukemia (AML). Relapse is driven by leukemia stem cells, a chemoresistant subpopulation capable of re-establishing disease. Patients with p53 mutant AML are at an extremely high risk of relapse. B-cell-specific Moloney murine...
Autores principales: | Nishida, Y, Maeda, A, Kim, M J, Cao, L, Kubota, Y, Ishizawa, J, AlRawi, A, Kato, Y, Iwama, A, Fujisawa, M, Matsue, K, Weetall, M, Dumble, M, Andreeff, M, Davis, T W, Branstrom, A, Kimura, S, Kojima, K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386342/ https://www.ncbi.nlm.nih.gov/pubmed/28211885 http://dx.doi.org/10.1038/bcj.2017.8 |
Ejemplares similares
-
Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma
por: Maeda, Aya, et al.
Publicado: (2018) -
BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
por: Seipel, Katja, et al.
Publicado: (2021) -
Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent
por: Jernigan, Finith, et al.
Publicado: (2021) -
Off-target effect of the BMI1 inhibitor PTC596 drives epithelial-mesenchymal transition in glioblastoma multiforme
por: Flamier, Anthony, et al.
Publicado: (2020) -
The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells
por: Nagai, Yurie, et al.
Publicado: (2021)